Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
OssDsign AB (publ.) today announces that the company expects its revenues for the fourth quarter of 2023 to exceed market expectations. Preliminary total revenues for the period October - November amount to SEK 25.2 million, mainly attributable to a continued strong market performance of the orthobiologics franchise and some extraordinary orders from a large hospital system.
According to preliminary and unaudited data, sales of OssDsign Catalyst amounted to SEK 18.8 million during the period of October - November 2023, whereas OssDsign Cranial recorded sales of SEK 6.4 million.
"The continued strong market performance of OssDsign Catalyst means we have already exceeded market expectations after only two months in the quarter and confirms the attractiveness of our recently announced strategy shift to fully focus on the high-margin orthobiologics franchise", said Morten Henneveld, CEO of OssDsign.
A complete financial statement for the fourth quarter will be presented in the year-end report for 2023, to be published on February 6, 2024.
This disclosure contains information that OssDsign AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 06-12-2023 08:00 CET.